NASDAQ:INKT MiNK Therapeutics (INKT) Stock Price, News & Analysis $0.90 -0.03 (-3.23%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.88▼$0.9550-Day Range$0.87▼$1.1452-Week Range$0.75▼$1.96Volume48,951 shsAverage Volume97,347 shsMarket Capitalization$31.20 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get MiNK Therapeutics alerts: Email Address MiNK Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside901.8% Upside$9.00 Price TargetShort InterestHealthy1.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.41) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.17 out of 5 starsMedical Sector410th out of 936 stocksBiological Products, Except Diagnostic Industry60th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingMiNK Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMiNK Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about MiNK Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.61% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently decreased by 10.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INKT. Previous Next 3.6 News and Social Media Coverage News SentimentMiNK Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MiNK Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows3 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.81% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.87% of the stock of MiNK Therapeutics is held by institutions.Read more about MiNK Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MiNK Therapeutics are expected to grow in the coming year, from ($0.41) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MiNK Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About MiNK Therapeutics Stock (NASDAQ:INKT)MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Read More INKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INKT Stock News HeadlinesJune 5, 2024 | globenewswire.comMiNK Therapeutics Announces Virtual Annual Shareholders MeetingMay 22, 2024 | finanznachrichten.deMiNK Therapeutics: MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual MeetingJuly 27, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 22, 2024 | globenewswire.comMiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual MeetingMay 15, 2024 | uk.finance.yahoo.comQ1 2024 Mink Therapeutics Inc Earnings CallMay 15, 2024 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...May 14, 2024 | investorplace.comINKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comMiNK Reports First Quarter 2024 ResultsJuly 27, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 13, 2024 | globenewswire.comMiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board ObserverApril 30, 2024 | finance.yahoo.comMiNK to Provide Corporate Update and First Quarter 2024 Financial ReportApril 30, 2024 | globenewswire.comMiNK to Provide Corporate Update and First Quarter 2024 Financial ReportApril 11, 2024 | finance.yahoo.comThis MiNK Therapeutics Insider Increased Their Holding In The Last YearApril 8, 2024 | globenewswire.comMiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACRMarch 25, 2024 | markets.businessinsider.comBuy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial MovesMarch 22, 2024 | insidermonkey.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comPromising Clinical Progress and Market Potential for MiNK Therapeutics’ agenT-797 in Gastric Cancer StudyMarch 21, 2024 | investorplace.comINKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023See More Headlines Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INKT CUSIPN/A CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+901.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,460,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-265.44% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.52) per share Price / Book-1.73Miscellaneous Outstanding Shares34,730,000Free Float28,543,000Market Cap$31.20 million OptionableNo Data Beta0.07 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Executive Chairman Dr. Jennifer S. Buell Ph.D. (Age 48)President, CEO & Director Comp: $916.75kDr. Marcus Antonius van Dijk Ph.D. (Age 62)Chief Scientific Officer Comp: $458.28kMs. Christine M. Klaskin (Age 58)Treasurer Comp: $29.62kJoy Zhou Ph.D.Vice President & Head of CMCKey CompetitorsBrainstorm Cell TherapeuticsNASDAQ:BCLICelyad OncologyNASDAQ:CYADCelularityNASDAQ:CELUAdicet BioNASDAQ:ACETTevogen BioNASDAQ:TVGNView All CompetitorsInsidersAgenus IncBought 429 shares on 10/16/2023Total: $471.90 ($1.10/share)Agenus IncBought 3,173 shares on 10/12/2023Total: $3,490.30 ($1.10/share)Agenus IncBought 15,001 shares on 10/4/2023Total: $16,351.09 ($1.09/share)Agenus IncBought 12,808 shares on 8/28/2023Total: $18,571.60 ($1.45/share)Agenus IncBought 170,244 shares on 8/24/2023Total: $262,175.76 ($1.54/share)View All Insider Transactions INKT Stock Analysis - Frequently Asked Questions How have INKT shares performed this year? MiNK Therapeutics' stock was trading at $1.07 on January 1st, 2024. Since then, INKT shares have decreased by 16.0% and is now trading at $0.8984. View the best growth stocks for 2024 here. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. When did MiNK Therapeutics IPO? MiNK Therapeutics (INKT) raised $43 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share. How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INKT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.